Europeiska unionen - svenska - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - immunsuppressiva - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - leukemi, myelogen, kronisk, bcr-abl positiv - antineoplastiska medel - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sanofi pasteur msd s.p.a. - influensavirus a/brisbane/10/2007 (h3n2)-liknande stam (a/uruguay/716/2007, nymc x-175c), ytantigen, inaktiverat; influensavirus a/brisbane/59/2007 (h1n1)-liknande stam (a/brisbane/59/2007, ivr-148), ytantigen, inaktiverat; influensavirus b/brisbane/60/2008-liknande stam (b/brisbane/60/2008), ytantigen, inaktiverat - injektionsvätska, suspension i emulsion i förfylld spruta - skvalan 9,75 mg adjuvans; citronsyra (vattenfri) 0,04 mg adjuvans; natriumcitrat (dihydrat) 0,66 mg adjuvans; sorbitantrioleat 1,175 mg adjuvans; influensavirus b/brisbane/60/2008-liknande stam (b/brisbane/60/2008), ytantigen, inaktiverat 15 mikrog aktiv substans; influensavirus a/brisbane/10/2007 (h3n2)-liknande stam (a/uruguay/716/2007, nymc x-175c), ytantigen, inaktiverat 15 mikrog aktiv substans; polysorbat 80 1,175 mg adjuvans; influensavirus a/brisbane/59/2007 (h1n1)-liknande stam (a/brisbane/59/2007, ivr-148), ytantigen, inaktiverat 15 mikrog aktiv substans - spjälkat virus eller ytantigen

Europeiska unionen - svenska - EMA (European Medicines Agency)

baxter holding b.v. - doxorubicinhydroklorid - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - antineoplastiska medel - caelyx pegylerat liposomala anges:som monoterapi för patienter med metastaserad bröstcancer, där det finns en ökad risk för hjärt -; för behandling av framskriden äggstockscancer hos kvinnor som har misslyckats med en första linje platinum-baserad kemoterapi behandling, i kombination med bortezomib för behandling av progressiv multipelt myelom hos patienter som har fått minst en tidigare behandling och som redan har genomgått eller är olämpliga för benmärgstransplantation, för behandling av aids-relaterat kaposis sarkom (ks) i patienter med låga cd4 räknas (.

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Europeiska unionen - svenska - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doxorubicinhydroklorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiska medel - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

teva sweden ab - terbinafinhydroklorid - kräm - 10 mg/g - terbinafinhydroklorid 10 mg aktiv substans; bensylalkohol hjälpämne; cetylalkohol hjälpämne; cetostearylalkohol hjälpämne - terbinafin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

rivopharm ltd. - terbinafinhydroklorid - kräm - 10 mg/g - bensylalkohol hjälpämne; cetylalkohol hjälpämne; stearylalkohol hjälpämne; terbinafinhydroklorid 10 mg aktiv substans - terbinafin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

evolan pharma ab - terbinafinhydroklorid - kräm - 10 mg/g - terbinafinhydroklorid 10 mg aktiv substans; stearylalkohol hjälpämne; cetylalkohol hjälpämne; bensylalkohol hjälpämne - terbinafin

Europeiska unionen - svenska - EMA (European Medicines Agency)

mylan s.a.s. - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - antineoplastiska medel - behandling av bröstcancer, speciella former av lungcancer (icke-småcellig lungcancer), prostatacancer, magcancer eller huvud och nackcancer.